DBP International: IMPD for the SI-053 phase I trial is finalized – nine out of ten milestones for the clinical trial of SI-053 have been completed
Double Bond Pharmaceutical International AB (publ) ("DBP") takes a step further towards the start of the phase 1 clinical trial of its front-line product SI-053 in patients with glioblastoma – the Investigational Medicinal Product Dossier (IMPD) for the upcoming trial is now compiled. The IMPD is a document which contains all the relevant drug development and quality information regarding the manufacturing, testing and packaging of APIs, excipients as well as investigational medicinal products. The document is a central piece of Investigational Medicinal Product (IMP) related documents